UY27323A1 - METHODS TO MANAGE ANTI-TNFA ANTIBODIES - Google Patents
METHODS TO MANAGE ANTI-TNFA ANTIBODIESInfo
- Publication number
- UY27323A1 UY27323A1 UY27323A UY27323A UY27323A1 UY 27323 A1 UY27323 A1 UY 27323A1 UY 27323 A UY27323 A UY 27323A UY 27323 A UY27323 A UY 27323A UY 27323 A1 UY27323 A1 UY 27323A1
- Authority
- UY
- Uruguay
- Prior art keywords
- tnfa
- antibodies
- antibody
- methods
- htnfa
- Prior art date
Links
Abstract
Mctodos para tratar trastornos en los cuales tienen ingerencia el TNFa, que comprenden la administracinn subcutrnea, cadda dos semanas, de anticuerpos humanos,preferiblemente anticuerpos recombinantes humanos, que se unen al factor de necrosis tumoral humano a (TNFa). El anticuerpo puede administrarse con o sin metotrexato. Estos anticuerpos tienen una alta afinidad por hTNFa ( por ejemplo , Kd = 10-8 M o menos) una baja velocidad de salida parala disociacinn con h TNFa ( por ejemplo, Koff = 10-3 sec-1 o menos) y neutralizan la active?idad de hTNFa in vitro e in vivo. Un anticuerpo de la invencinn puede ser un anticuerpo completo o una porcinn de uninn a antigeno del mismo. Tambicn se incluyen conjuntos de alementos (kits) que contienen una composicinn farmaccutica e instrucciones para su dosificacinn, y jeringas cargadas que contienen composiciones farmaccuticas.Methods for treating disorders in which TNFa have interference, which comprise the subcutaneous administration, within two weeks, of human antibodies, preferably human recombinant antibodies, which bind to human tumor necrosis factor a (TNFa). The antibody can be administered with or without methotrexate. These antibodies have a high affinity for hTNFa (for example, Kd = 10-8 M or less) a low output rate for dissociation with h TNFa (for example, Koff = 10-3 sec-1 or less) and neutralize the active ity of hTNFa in vitro and in vivo. An antibody of the invention may be a complete antibody or a portion of an antigen to an antigen thereof. Also included are sets of alloys (kits) containing a pharmaceutical composition and instructions for dosing, and loaded syringes containing pharmaceutical compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY27323A UY27323A1 (en) | 2002-06-07 | 2002-06-07 | METHODS TO MANAGE ANTI-TNFA ANTIBODIES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY27323A UY27323A1 (en) | 2002-06-07 | 2002-06-07 | METHODS TO MANAGE ANTI-TNFA ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27323A1 true UY27323A1 (en) | 2003-01-31 |
Family
ID=38812655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27323A UY27323A1 (en) | 2002-06-07 | 2002-06-07 | METHODS TO MANAGE ANTI-TNFA ANTIBODIES |
Country Status (1)
| Country | Link |
|---|---|
| UY (1) | UY27323A1 (en) |
-
2002
- 2002-06-07 UY UY27323A patent/UY27323A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034867A (en) | METHODS TO MANAGE ANTI-TNFa ANTIBODIES | |
| UY27780A1 (en) | USE OF ANTI-TNF ALPHA AND OTHER DRUG ANTIBODIES | |
| EA201992590A1 (en) | STABLE COMPOSITIONS OF ANTIBODIES TO THE RECIPE OF PROGRAMMABLE DAMAGE 1 (PD-1) AND WAYS OF THEIR APPLICATION | |
| RU2421464C2 (en) | Human il-13 antibodies and their therapeutic application | |
| CY1126062T1 (en) | STABLE PHARMACEUTICAL FORM OF ANTI-IFNAR1 | |
| EA201992765A1 (en) | PROTEINS BASED ON ANTIBODIES WITH VACCINATED CYTOKINE AND METHODS OF THEIR APPLICATION IN TREATMENT OF CANCER | |
| HRP20110334T1 (en) | Tgf beta 1 specific antibodies | |
| BRPI0507680A (en) | therapeutic calcium phosphate particles and methods of manufacture and use thereof | |
| UA116194C2 (en) | ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN | |
| PE20070116A1 (en) | FORMULATION OF STABLE ANTIBODIES | |
| ATE535252T1 (en) | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE | |
| BR0008161A (en) | Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell | |
| DE60332277D1 (en) | ADMINISTRATION OF SIRNAS | |
| UA112743C2 (en) | THERAPEUTIC DLL4 Binding Protein | |
| RU2014123990A (en) | ANTIBODY TO ADRENOMEDULLIN (ADM) OR ANTI-ADM ANTIBODY FRAGMENT OR ANTI-ADM HE-IQ FRAME FOR USE IN THERAPY | |
| EA200600254A1 (en) | HUMAN NEUTRALIZING ANTIBODIES TO THE NERVE GROWTH FACTOR (NGF) AS A SELECTIVE NGF METABOLIC INHIBITOR | |
| AR033978A1 (en) | ANTIBODY MOLECULA WITH SPECIFICITY FOR HUMAN ALPHA TUMOR NECROSIS FACTOR AND USES OF THE SAME | |
| Hajinejad et al. | Resveratrol pretreatment enhanced homing of SDF‐1α‐preconditioned bone marrow‐derived mesenchymal stem cells in a rat model of liver cirrhosis | |
| RU2018146886A (en) | WAYS OF THERAPEUTIC USE OF C-RAF INHIBITOR | |
| EA200501821A1 (en) | PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION | |
| DE60137146D1 (en) | FUSION CELLS AND CYTOKINE COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| EA202193240A1 (en) | STABILIZED COMPOSITIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES | |
| DK0981362T3 (en) | Use of GLP-2 agonists to improve the function of the upper gastrointestinal tract | |
| BRPI0407649A (en) | liquid formulation of tumor necrosis factor binding proteins, process for preparing liquid formulation of tumor necrosis factor binding proteins and formulation presentation form | |
| UY27323A1 (en) | METHODS TO MANAGE ANTI-TNFA ANTIBODIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160616 |